Hedefe Yönelik Alfa Tedavisi Fiziksel Prensiplerden Klinik Uygulamaya

Toklu T. Physical and Radiobiological Properties of Alpha Emitter Isotopes Used in Radionuclide Therapy. nts. 2023 Sep 1;9(2):96–101.

Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep 1;19(9):589–608.

Lewis JS, Windhorst AD, Zeglis BM, editors. Radiopharmaceutical Chemistry [Internet]. Cham: Springer International Publishing; 2019 [cited 2026 Jan 21]. Available from: https://link.springer.com/10.1007/978-3-319-98947-1

Nelson BJB, Andersson JD, Wuest F. Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications. Pharmaceutics. 2020 Dec 31;13(1):49.

Miederer M, Benešová-Schäfer M, Mamat C, Kästner D, Pretze M, Michler E, et al. Alpha-Emitting Radionuclides: Current Status and Future Perspectives. Pharmaceuticals. 2024 Jan 8;17(1):76.

Ahenkorah S, Cassells I, Deroose CM, Cardinaels T, Burgoyne AR, Bormans G, et al. Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside. Pharmaceutics. 2021 Apr 21;13(5):599.

Ferrier MG, Radchenko V, Wilbur DS. Radiochemical aspects of alpha emitting radionuclides for medical application. Radiochimica Acta. 2019 Sep 25;107(9–11):1065–85.

Bolin J, Groves D. Targeted Alpha Radiopharmaceutical Therapy and Key Considerations for Nuclear Medicine Technologists. World J Nucl Med. 2025 Sep;24(03):192–203.

Beydağı G, Alan Selçuk N, Kabasakal L. Alpha Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors. nts. 2023 Sep 1;9(2):109–15.

Ünak P, Tutun E. Current Approach to Potential Alpha Particle Emiting Radionuclides for Alpha Radionuclide Therapy. In: Nuclear Medicine Seminars [Internet]. Nuclear Medicine Seminars; 2023 [cited 2026 Jan 21]. Available from: https://nukleertipseminerleri.org/articles/current-approach-to-potential-alpha-particle-emiting-radionuclides-for-alpha-radionuclide-therapy/doi/nts.galenos.2023.0002

Ocak M, Akit AA, Ünak P. Targeted Alpha Radionuclide Therapy (TAT)-Ac-225 Radiopharmaceuticals. nts. 2023 Mar 1;9(1):16–24.

Eychenne R, Chérel M, Haddad F, Guérard F, Gestin JF. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight.” Pharmaceutics. 2021 Jun 18;13(6):906.

Tosato M, Favaretto C, Kleynhans J, Burgoyne AR, Gestin JF, Van der Meulen NP, et al. Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy. Nuclear Medicine and Biology. 2025;142:108990.

Bruchertseifer F, Kellerbauer A, Malmbeck R, Morgenstern A. Targeted alpha therapy with bismuth‐213 and actinium‐225: Meeting future demand. Labelled Comp Radiopharmac. 2019 Sep;62(11):794–802.

Hooijman EL, Chalashkan Y, Ling SW, Kahyargil FF, Segbers M, Bruchertseifer F, et al. Development of [225Ac]Ac-PSMA-IT for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC. Pharmaceutics. 2021 May 13;13(5):715.

Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, et al. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018 May;45(5):824–45.

Ocak M, Kabasakal L. Targeted Alpha Therapy-Promising Radionuclides Beyond Ac-225. In: Nuclear Medicine Seminars [Internet]. Nuclear Medicine Seminars; 2023 [cited 2026 Jan 21]. Available from: https://nukleertipseminerleri.org/articles/targeted-alpha-therapy-promising-radionuclides-beyond-ac-225/doi/nts.galenos.2023.0017

Ninatti G, Scilipoti P, Pini C, Barletta F, Longoni M, Gelardi F, et al. Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysis. Theranostics. 2025 Feb 20;15(8):3386–99.

Hofmann W, Li WB, Friedland W, Miller BW, Madas B, Bardiès M, et al. Internal microdosimetry of alpha-emitting radionuclides. Radiat Environ Biophys. 2020 Mar;59(1):29–62.

Targeted Alpha Therapy Working Group, Parker C, Lewington V, Shore N, Kratochwil C, Levy M, et al. Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review. JAMA Oncol. 2018 Dec 1;4(12):1765.

Kratochwil C, Haberkorn U, Giesel FL. 225Ac-PSMA-617 for Therapy of Prostate Cancer. Seminars in Nuclear Medicine. 2020 Mar;50(2):133–40.

Selçuk NA, Akçay K, Kabasakal L. The Role of Alpha Therapy in Metastatic Castration Resistance Prostate Cancer. Nukleer Tıp Seminerleri. 2023;9(2):102.

Guerra Liberal FDC, O’Sullivan JM, McMahon SJ, Prise KM. Targeted Alpha Therapy: Current Clinical Applications. Cancer Biotherapy and Radiopharmaceuticals. 2020 Aug 1;35(6):404–17.

Qin Y, Imobersteg S, Blanc A, Frank S, Schibli R, Béhé MP, et al. Evaluation of Actinium-225 Labeled Minigastrin Analogue [225Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy. Pharmaceutics. 2020 Nov 12;12(11):1088.

Yoshimoto M, Yoshii Y, Matsumoto H, Shinada M, Takahashi M, Igarashi C, et al. Evaluation of Aminopolycarboxylate Chelators for Whole-Body Clearance of Free 225Ac: A Feasibility Study to Reduce Unexpected Radiation Exposure during Targeted Alpha Therapy. Pharmaceutics. 2021 Oct 16;13(10):1706.

Bell MM, Gutsche NT, King AP, Baidoo KE, Kelada OJ, Choyke PL, et al. Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma. Molecules. 2020 Dec 22;26(1):4.

Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, et al. Radiotheranostics: a roadmap for future development. The Lancet Oncology. 2020 Mar;21(3):e146–56.

Özdemir E. Radium-223 for the Treatment of Painful Bone Metastates in Castration-resistant Prostate Cancer. nts. 2023 Sep 1;9(2):116–23.

Zacherl MJ, Gildehaus FJ, Mittlmeier L, Böning G, Gosewisch A, Wenter V, et al. First Clinical Results for PSMA-Targeted α-Therapy Using225 Ac-PSMA-IT in Advanced-mCRPC Patients. J Nucl Med. 2021 May 10;62(5):669–74.

Rosar F, Krause J, Bartholomä M, Maus S, Stemler T, Hierlmeier I, et al. Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis. Pharmaceutics. 2021 May 14;13(5):722.

Ballal S, Yadav MP, Sahoo RK, Tripathi M, Dwivedi SN, Bal C. 225 Ac‐PSMA‐617‐targeted alpha therapy for the treatment of metastatic castration‐resistant prostate cancer: A systematic review and meta‐analysis. The Prostate. 2021 Jun;81(9):580–91.

Feuerecker B, Kratochwil C, Ahmadzadehfar H, Morgenstern A, Eiber M, Herrmann K, et al. Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution? J Nucl Med. 2023 May;64(5):685–92.

Garo ML, Ovčariček PP, Fanti S, Giovanella L. [225 Ac]Ac‐PSMA for the treatment of metastatic castration‐resistant prostate cancer: A systematic review and meta‐analysis. Eur J Clin Investigation. 2025 May;55(5):e14358.

Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, et al. 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):721–8.

Şahin OE. Alfa Radyonüklid Tedavilerinde Aktif Faz Çalışmaları. Nucl Med Semin. 2023;9:133–9.

Ballal S, Yadav MP, Bal C, Sahoo RK, Tripathi M. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):934–46.

Delpassand ES, Tworowska I, Esfandiari R, Torgue J, Hurt J, Shafie A, et al. Targeted α -Emitter Therapy with212 Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial. J Nucl Med. 2022 Sep;63(9):1326–33.

Kunikowska J, Morgenstern A, Pełka K, Bruchertseifer F, Królicki L. Targeted alpha therapy for glioblastoma. Front Med (Lausanne). 2022 Dec 16;9:1085245.

Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008 Jan;49(1):30–8.

Behling K, Maguire WF, Di Gialleonardo V, Heeb LEM, Hassan IF, Veach DR, et al. Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles. J Nucl Med. 2016 Nov;57(11):1771–7.